Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of TP-05 (Callisto)
NCT05138796Phase 1Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lotilaner in Lyme disease (6 arms), sponsored by Tarsus Pharmaceuticals, Inc. Primary endpoints: Incidence of treatment emergent adverse events up to 151 days, Clinically significant changes from Baseline laboratory tests (chemistry, hematology) up to 151 days and 2 more. Started May 2021; status: completed.
02
Drugs
lotilaner
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT05138796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138796.